within Pharmacolibrary.Drugs.ATC.J;

model J05AH03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.16833333333333333,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.01256,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Peramivir is a neuraminidase inhibitor antiviral drug used for the treatment of influenza. It is administered primarily as a single-dose intravenous infusion for adults with acute uncomplicated influenza. Peramivir is approved for use in the United States and several other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single 600 mg intravenous dose.</p><h4>References</h4><ol><li>Lu Li, Xin Li, Yanzhe Xia, Yanqi Chu, Haili Zhong, Jia Li, Pei Liang, Yishan Bu, Rui Zhao, Yun Liao, Ping Yang, Xiaoyang Lu, Saiping Jiang,Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.,Frontiers in pharmacology,2020<a href='https://pubmed.ncbi.nlm.nih.gov/32547394/'>https://pubmed.ncbi.nlm.nih.gov/32547394/</a></li><li>Dan Zhang, Aihua Du, Lina Zhang, Jingyi Ma, Lingjie Meng, Ming Deng, Juan Xu, Huichen Liu,Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects.,Xenobiotica; the fate of foreign compounds in biological systems,2015<a href='https://pubmed.ncbi.nlm.nih.gov/25231091/'>https://pubmed.ncbi.nlm.nih.gov/25231091/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AH03;
